Ribon Therapeutics (@RibonTx) / X

RBN-3143 – Reducing Th17 and Th2 signaling to treat multiple inflammatory diseases through PARP14 inhibition – Ribon Therapeutics

Ribon Therapeutics (@RibonTx) / X

Molecules, Free Full-Text

Investors – Ribon Therapeutics

Ribon Therapeutics Raises $65 Million to Advance Pipeline of Novel Therapeutics Targeting Cellular Stress Pathways for Cancer

Ribon Therapeutics Announces $25 Million Equity Investment from

PDF) Forced Self-Modification Assays as a Strategy to Screen MonoPARP Enzymes

Heike Keilhack (@haxe73) / X

Forced Self-Modification Assays as a Strategy to Screen MonoPARP Enzymes - Tim J. Wigle, W. David Church, Christina R. Majer, Kerren K. Swinger, Demet Aybar, Laurie B. Schenkel, Melissa M. Vasbinder, Arne

Ribon Therapeutics (@RibonTx) / X

Articles about Ribon Therapeutics